ANEBULO PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.07% for the 9-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-05-13
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-12-31 was 4.07%, a 14.68% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.27%.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-12-31 was 4.77%.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-09-30 was 4.62%, a 60.98% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month |
|---|---|---|---|
| 2025-03-31 | 4.07% 10-Q · filed 2025-05-13 | ||
| 2024-12-31 | 4.07% 10-Q · filed 2025-02-14 | 4.07% 10-Q · filed 2025-02-14 | |
| 2024-03-31 | 4.27% 10-Q · filed 2025-05-13 | ||
| 2023-12-31 | 4.77% 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | 4.62% 10-Q · filed 2024-11-13 | ||
| 2022-09-30 | 2.87% 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |